MCR - Aptneo

Atezolizumab, Pertuzumab and Trastuzumab with chemotherapy as neoadjuvant treatment of HER2 positive early high-risk and locally advanced breast cancer (APTneo).

PHASE

III

NCT Number

NCT03595592

DEFINITION

Pharmacological

SPONSOR

Fondazione Michelangelo